Horizon Pharma plc / Hyperion Therapeutics, Inc.

Urea Cycle Disorders (UCD)

113 US cases/yr · $127M Hyperion 2014 Ravicti + Buphenyl combined revenue (US-dominant)

Disease Overview

Urea cycle disorders are rare inherited metabolic conditions where one of six liver enzymes that convert ammonia to urea is deficient, causing toxic ammonia accumulation. They typically present in newborns with hyperammonemic crises that can cause brain damage or death; chronic management requires protein restriction plus nitrogen-scavenging drugs for life.

Competitive Landscape

The UCD chronic-maintenance market is structurally limited: only two oral nitrogen-scavenger franchises were FDA-approved at deal time. Buphenyl (sodium phenylbutyrate, originally Ucyclyd Pharma) was the legacy standard but suffered from a famously bitter taste, high sodium content, and pill burdens up to 40 tablets/day. Ravicti (glycerol phenylbutyrate), approved February 2013, is a tasteless oral liquid pro-drug that became the chronic-care successor product; Hyperion paired it with Buphenyl to cover all ages including infants under two. Ammonul (sodium phenylacetate/sodium benzoate IV, retained by Ucyclyd) addresses acute hyperammonemic crises in hospital and is not a true chronic competitor. Outside the US, sodium benzoate and Pheburane (sodium phenylbutyrate pellets, Lucane Pharma) compete in EU markets. The deal handed Horizon a near-monopoly position in US chronic UCD therapy with Ravicti as the growth driver — Hyperion projected 2015 Ravicti sales of $107-113M plus $13-15M for Buphenyl. Horizon paid roughly 9x revenue for an orphan franchise with high pricing power, expanded specialty pharmacy infrastructure, and a defensible patient base. Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC8898712/